Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "free cc dumps with pin, 【 Visit Amsiga.com 】 ojM3t2s., dumpscvv, buy bin cc, rescator shop LfYM"

Looking for quality documents?
external link icon
Repligen Corporation Announces Agreement to Acquire Process Analytics Innovator C Technologies and Reports Preliminary First Quarter 2019 Financial Results
Proposed acquisition establishes a key franchise for Repligen in the rapidly growing Process Analytics segment of bioprocessing
Adds a market leader in protein concentration measurement with proprietary and differentiated spectroscopy technology Complements and advances our systems strategy in Chromatography and Filtration C Technologies is expected to contribute approximately $16-$17 million in revenue and be accretive to Repligen’s adjusted earnings per share in 2019 Repligen reports preliminary first quarter 2019 financial results, highlighted by 35%-37% year-over-year organic growth WALTHAM, Mass., April 26, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held C Technologies, Inc. for approximately $240 million, comprised of $192 million in cash plus $48 million in Repligen common stock. C Technologies
external link icon
Repligen to Participate in 13th Annual Craig-Hallum Institutional Investor Conference
WALTHAM, Mass., May 26, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today announced that it will participate in the 13 th Annual Craig-Hallum Institutional Investor Conference being held on June 1 in Minneapolis, MN. This conference provides institutional investors the opportunity to meet with Company management and does not include a formal presentation. Repligen’s most recent investor presentation will be accessible through the Investor Events section of Company’s website.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A
corporate icon
Multicomponent Analysis
Challenge: Monitoring multiple analytes simultaneously is difficult with single-channel sensors. Our Solution: Variable pathlength technology supports spectral deconvolution and simultaneous quantification of key analytes.
external link icon
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices
Portfolio includes PAT devices for real-time process monitoring, control and analysis WALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc . (Nasdaq: MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices’ desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on the growth of its newly expanded handheld device portfolio for vital health and safety applications. The addition of these desktop assets complements and strengthens Repligen’s differentiated PAT portfolio that provides its biopharmaceutical and CDMO customers with actionable insights to optimize development processes and improve manufacturing efficiencies. Products acquired from 908 Devices include MAVERICK and MAVEN for real-time
external link icon
Repligen Reports First Quarter 2024 Financial Results
Reports first quarter revenue of $151 million Increased new modalities revenue by 16% year-over-year Increased Filtration (non-COVID) revenue by 12% year-over-year Achieved a nine-month book-to-bill ratio of 1.03 WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter (Q1) of 2024, covering the three-month period ended March 31, 2024. The company also reiterated its financial guidance for the full year 2024. Tony J. Hunt, Chief Executive Officer of Repligen said, “We delivered a solid first quarter, with revenue of $151 million and are on track to achieving our first half sales target of $300 to $310 million. For the quarter, our book-to-bill ratio was 0.99 and over the past nine months we achieved a book-to-bill of 1.03; indicative that our markets are recovering, albeit slowly. On a franchise level, our Filtration franchise
external link icon
Repligen Reports Second Quarter 2013 Financial Results
- Product Revenue Grows 12% for the Quarter on Record Bioprocessing Sales - - Net Income Grows 189% to $4.5 Million - - Earnings Conference Call and Webcast Today at 9:00 a.m. EDT - WALTHAM, Mass., Aug. 1, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today reported financial results for the second quarter ended June 30, 2013. Below are the Company's financial and business highlights for the second quarter of 2013, financial guidance for the year and dial-in numbers for today's conference call. Second Quarter 2013 Financial Highlights Bioprocessing product revenue for the second quarter of 2013 reached a record $13.0 million, an increase of 12% over the second quarter of 2012.
  Total revenue for the second quarter of 2013 was $17.5 million, an increase of 13% over the second quarter of 2012.
  Bioprocessing product gross profit margin was 59% for the second quarter of 2013, compared with 37% during the second quarter of 2012.
  Net income
external link icon
Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock
WALTHAM, Mass., April 29, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today announced that it has commenced an underwritten public offering of $175,000,000 in shares of its common stock. In addition, Repligen Corporation expects to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 in shares of its common stock in connection with the proposed public offering. All shares of common stock will be offered by Repligen Corporation. Repligen Corporation expects to use the net proceeds to fund the cash portion of the purchase price for its previously announced proposed acquisition of C Technologies, Inc. and for working capital and other general corporate purposes. J.P. Morgan Securities LLC and Stephens Inc. are acting as joint book-running managers for the offering. Janney Montgomery Scott is acting as lead manager for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the
external link icon
Repligen Announces Pricing of $100 Million of 2.125% Convertible Senior Notes due 2021
WALTHAM, Mass., May 19, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) (the “Company”) today announced the pricing of an underwritten public offering of $100 million aggregate principal amount of 2.125% Convertible Senior Notes due 2021 (the “Notes”). The Company has granted the underwriters a 30-day option to purchase up to an additional $15 million aggregate principal amount of Notes. The offering is expected to close on or about May 24, 2016, subject to customary closing conditions. Jefferies is acting as the sole book-running manager, and Janney Montgomery Scott and Craig-Hallum Capital Group are acting as co-managers in the offering.  Perella Weinberg Partners LP and J. Wood Capital Advisors LLC are serving as financial advisors to the Company in connection with the offering.
Interest on the Notes will be paid semiannually in arrears on June 1 and December 1 of each year at the rate of 2.125% per year, beginning on December 1, 2016. The Notes will
corporate icon
Perfusion Cell Culture
Perfusion, a cornerstone of upstream continuous bioprocessing, has been practiced since the 1980s to maximize facility utilization, expand process flexibility and minimize costs. Today, novel cell retention devices and single-use technologies, with sophisticated control logic, simplify implementation.
external link icon
Repligen Completes Expansion of U.S. Manufacturing Facility
WALTHAM, Mass., Nov. 1, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced it has completed a 9,000 square foot expansion of its manufacturing facilities at its Waltham headquarters to meet growth in demand for its bioprocessing products and to ensure that the quality, capacity and support needs of its customers continue to be met. A dedicated production suite more than doubles capacity for the Company's OPUS ® line of pre-packed chromatography columns, with cleanrooms built to ISO 7 specifications providing an appropriately controlled environment to satisfy the Good Manufacturing Practices (GMP) standards of the Company's biopharmaceutical customers. "This expansion will enable us to meet the critical needs of our customers for quality and timely delivery," said Walter C. Herlihy, Ph.D., President and Chief Executive Officer of Repligen. "The new cleanroom suite enables us to produce OPUS ® columns under the highest quality standard demanded by
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support